Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes

被引：0

作者：

Loriot, Yohann

Gupta, Shilpa

Powles, Thomas

Grivas, Petros

Petrylak, Daniel P.

Tyroller, Karin

Jacob, Natalia

Hoffman, Jason

Bellmunt, Joaquim

机构：

[1] Univ Paris Saclay, Gustave Roussy, INSERM, U981, Villejuif, France

[2] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[3] Queen Mary Univ London, Barts Canc Inst, St Bartholomews Hosp, Expt Canc Med Ctr, London, England

[4] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA 98195 USA

[5] Yale Canc Ctr, New Haven, CT USA

[6] EMD Serono, Billerica, MA USA

[7] Healthcare Business Merck KGaA, Darmstadt, Germany

[8] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[9] Harvard Med Sch, Boston, MA 02115 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4567

引用

页数：1